In this study, we use a competing risks analysis to assess factors predictive of early-salvage whole brain radiotherapy (WBRT) and early death after upfront stereotactic radiosurgery (SRS) alone for brain metastases in an attempt to identify populations that benefit less from upfront SRS.
Introduction
The use of stereotactic radiosurgery (SRS) for the treatment of brain metastases has increased in recent years due both to the increasing availability of technology [1] as well as publication of randomized trials showing improvements in cognition over combined-modality therapy based on whole brain radiotherapy (WBRT) [2, 3] . Previously published randomized trials comparing SRS alone to SRS þ WBRT were limited to patients having four or fewer brain metastases [2] [3] [4] [5] ; however, a recent multiinstitutional prospective observational study from Japan has reported that patients with up to 10 brain metastases can be treated with SRS alone, and that these patients have survival similar to patients with 2-4 metastases [6] . As such, it has become less clear as to which patients should be treated with upfront SRS without WBRT.
The cost of SRS is approximately three-to sixfold higher than WBRT in the United States [7, 8] , with overall differences in cost exacerbated by the fact that SRS patients also require more salvage procedures than those receiving WBRT [4] . With $170 000 patients in the United States diagnosed with brain metastases each year [9] , the appropriation of resources for brain metastasis management is a large-scale clinical dilemma. The use of SRS monotherapy appears to improve quality of life [10] and cognition [2, 3] over the use of WBRT, and although neurocognitive symptoms often begin to manifest within 3 months following WBRT [11] , there is no apparent plateau in incidence or severity of symptoms [12] . Based upon cognitive outcomes, it would therefore seem reasonable to treat with SRS rather than WBRT when possible, however, patients who have poor life expectancy or rapid development of multiple new brain metastases may not derive significant benefit from SRS as they are unlikely to live long enough to experience WBRT neurocognitive sequelae.
The goal of the present study is to assess, in patients treated upfront with SRS alone, the competing risks of distant brain failure (DBF) and the need for salvage therapy versus the risk of death prior to DBF or salvage therapy. A total of eight academic medical centers with high-volume SRS programs contributed data to the current analysis.
Methods

Data acquisition
This study was approved by the Institutional Review Board at all eight participating institutions. Data were reviewed and collected at all institutions for patients treated between 1 January 2000 and 1 January 2014. Patients were included in the study if they underwent SRS following initial diagnosis with brain metastasis. Electronic medical records were reviewed, and putative predictors of DBF and salvage therapy were recorded for each patient [13] . Extent of extracranial disease was defined based upon prior publications [14] . SRS doses varied by institution, but were generally determined based upon the guidelines published by Shaw et al. for single fraction radiosurgical treatment of brain metastases [15] . As SRS dose is inversely proportional to tumor volume, the lowest SRS dose prescribed to any lesion was recorded for each patient to serve as a surrogate for tumor volume.
The majority of patients underwent follow-up with magnetic resonance imaging (MRI) 1-3 months after their SRS procedures, with subsequent MRIs every 3 months thereafter. DBF events were defined as the development of one or more new brain metastases outside of the previous SRS target volume (s) . DBF events and the number of brain metastases at time of DBF were determined based upon MRI results.
Statistical analysis
Median follow-up and time-to-event outcomes were defined beginning at the time of SRS and extending to the time of most recent follow-up or to the event of interest. Time-to-event outcomes were summarized using the Kaplan-Meier method. Cumulative incidences were estimated for DBF, death prior to DBF/salvage, first salvage SRS, and first salvage WBRT [16] . Competing risks models were developed to determine the single variable subdistribution hazard ratios (HR) associated with each predictor for each of these events. Statistically significant (P < 0.05) variables identified on univariate analysis were included in forward stepwise regressions to identify the multivariable models that minimized the Akaike information criterion (AIC) [17] . These results were used to guide purposeful development of multivariate competing risks models for DBF versus death prior to DBF as well as first salvage with SRS versus first salvage with WBRT versus death prior to salvage.
Linear regression was carried out for predictor variables of interest for the outcome of number of brain metastases at time of DBF (nDBF). The linear regression analysis was limited to patients who experienced DBF and who had a quantifiable number of metastases at time of failure.
Stepwise regression was used to identify the nDBF multiple regression model with the lowest AIC [17] . Statistical analysis was carried out using R version 3.2.1 software (R Foundation for Statistical Computing, Vienna, Austria).
Results
Clinical outcomes
Of 2657 patients treated with upfront SRS alone, 2208 (83.1%) patients were deceased at the time of analysis, with DBF occurring in 1244 (46.8%) of all patients. Patient characteristics can be found in Table 1 . Median overall survival (OS) was 9.8 months (95% CI: 9.3-10.4 months). After initial SRS, a total of 619 (23.3%) patients received salvage SRS and 447 (16.8%) of patients received salvage WBRT after initial SRS. Of the 447 patients who received salvage WBRT, 336 (75.2%) received salvage WBRT as their first salvage treatment.
DBF versus death prior to DBF
The estimated cumulative incidences of DBF at 6, 12, and 24 months were 27.7%, 38.5%, and 46.0%, respectively ( Figure 1 ). Predictors of DBF identified on univariate analysis included age (P < 0.001), KPS (P < 0.001), systemic disease status (P < 0.001), number of brain metastases (P < 0.001), SRS dose (P < 0.001), and melanoma histology (P < 0.001). Cumulative incidences of DBF as stratified by variables included in the final multivariate analysis (MVA) model can be found in Figure 2 . Cumulative incidences of DBF at 1 and 2 years as stratified by all clinical variables of interest can be found in supplementary Table S1 , available at Annals of Oncology online. MVA identified an increased hazard of DBF associated with increasing number of brain metastases (HR ¼ 1.09, P < 0.001), lowest SRS dose (HR ¼ 1.04, P <0.001), and melanoma histology (HR ¼ 1.37, P < 0.001), while there was a decreased hazard of DBF associated with increasing age (HR ¼ 0.99, P < 0.001), KPS < 70 (HR ¼ 0.59, P < 0.001), and progressive systemic disease (HR ¼ 0.84, P ¼ 0.004) ( Table 2 ).
First salvage: SRS versus WBRT versus death prior to salvage
The estimated cumulative incidences of first salvage with SRS at 6, 12, and 24 months were 10.1%, 15.4%, and 19.4%, respectively ( Figure 1 ). The estimated cumulative incidences of first salvage with WBRT at 6, 12, and 24 months were 8.5%, 11.1%, and 12.9%, respectively. MVA for first salvage WBRT revealed an increased hazard with increasing number of brain metastases (HR ¼ 1.09, P < 0.001) and a decreased hazard with widespread systemic disease (HR ¼ 0.67, P ¼ 0.002) and increasing age (HR ¼ 0.98, P < 0.001). MVA for first salvage SRS revealed an increased hazard with increasing lowest SRS dose (HR ¼ 1.12, P <0.001), and a decreased hazard with KPS < 70 (HR ¼ 0.30, P <0.001). Progressive systemic disease was associated with an increased hazard of death prior to salvage with either SRS or WBRT (HR ¼ 1.69, P < 0.001), and a decreased hazard of both first salvage WBRT (HR ¼ 0.65, P <0.001) and first salvage SRS (HR ¼ 0.69, P < 0.001) on respective MVAs. MVA results for first salvage WBRT and first salvage SRS can be found in Table 2 . Cumulative incidences of first salvage WBRT as stratified by variables included in the final MVA model can be found in supple mentary Figure S1 , available at Annals of Oncology online. Cumulative incidences of first salvage WBRT at 1 and 2 years as stratified by all clinical variables of interest can be found in supple mentary Table S1 , available at Annals of Oncology online.
Number of brain metastases at time of DBF
Of the 1244 patients with DBF, there were 924 patients (74.3%) who had a quantifiable number of brain metastases at time of initial DBF (nDBF). On multiple regression, increasing age was associated with lower nDBF (P ¼ 0.02), while systemic disease status (P ¼ 0.03), melanoma histology (P ¼ 0.05), and higher number of initial brain metastases (P < 0.001) were associated with higher nDBF, as shown in supplementary Table S2 , available at Annals of Oncology online. When patients were analyzed by histologic subset, initial number of brain metastases was predictive of nDBF for lung (P ¼ 0.001), RCC (P ¼ 0.006), and melanoma (P < 0.001), but was not predictive of nDBF for patients with breast cancer (P ¼ 0.29) (supplementary Figure S2 , available at Annals of Oncology online).
Discussion
Identification of populations that do and do not benefit from SRS will be critical for the proper appropriation of a costly resource. Treating patients with a severely limited life expectancy is unlikely to be a cost-effective use of SRS given the high cost relative to a short-term benefit. As the cognitive toxicity of WBRT is permanent, those with a longer life expectancy may experience the greatest benefit from postponement or complete avoidance of WBRT [12] . The median life expectancy of patients with brain metastases in the modern era is $8-10 months, though the range is wide [4] [5] [6] . The tail of this range will likely broaden further with the increasing use and availability of novel systemic treatment options such as checkpoint inhibitors that seem to be significantly prolonging survival for some patients, as notably shown recently with advanced melanoma [18] . As such, prognostic indices that help to identify populations with particularly poor prognoses will be helpful for clinical decision-making [19] . In the current analysis, poor performance status, progressive systemic disease and larger brain metastases (lower SRS dose) predicted for early death after SRS alone. Those with a low burden of brain disease and short life expectancy may be best treated with supportive care or observed until symptomatic [20] . Those with a high total volume of metastatic brain disease have a poorer prognosis and greater likelihood of dying of brain metastases, and may warrant consideration of upfront WBRT [21] , as large brain metastases treated with SRS alone have previously been associated with a higher likelihood of neurologic death [22] . These patients may be best treated with fractionated SRS or a multimodality approach such as WBRT followed by SRS boost, SRS followed by surgery, or surgery followed by radiotherapy. The threshold number of brain metastases that should be treated with SRS monotherapy remains controversial. Published randomized trials have used a limit of 3-4 brain metastases [2] [3] [4] , though a prospective study from Japan suggests that up to 10 can be treated with equivalent survival [6] . Traditionally, such a limit was posed because treating larger numbers of metastases would overwhelm the capacity of many linear accelerator-based radiosurgery platforms. With recent improvements, these technical limitations are no longer as relevant [1] . Multiple series have suggested that the total volume of brain metastases is likely more important than the number of metastases at time of SRS with regards to OS [6, 23] . However, other series have implied that a greater number of metastases predicts for earlier DBF [13, 24] , as seen in the present series.
While the optimal upfront modality for brain metastasis management has been heavily investigated, the criteria for optimal use of each salvage modality remain undetermined. As previously mentioned, the number of new metastases at time of DBF is a dominant determinant of whether WBRT or SRS will be used in the salvage setting [25, 26] . Patients who receive multiple salvage SRS procedures for a limited number of brain metastases may represent a population who have survived the competing risks of early death and early WBRT. Conversely, those who experience an acceleration of intracranial progression likely require WBRT at the point of acceleration. The recently introduced concept of brain metastasis velocity is one in which the re-seeding rate of the brain is used to triage patients to salvage modality [25] . While this concept remains to be validated, it has potential in aiding practice decisions and is supported by the finding in the current study that patients with greater number of metastases at time of diagnosis also have a greater number at time of treatment failure.
Brain metastasis patients have a large competing risk of dying of their extracranial disease, with only 20% of patients actually dying of brain metastases [5] . The results of the current study support this notion, as patients with widespread extracranial disease were less likely to receive salvage WBRT. Previous reports have suggested, though, that those with early CNS failure are at higher risk of dying of neurologic death [27] . Patients who require early WBRT often do so because of rapid multifocal DBF, leptomeningeal seeding or large volume local failure. Should these events occur within several weeks after brain metastasis diagnosis, patients may be less likely to benefit from SRS because of the lack of meaningful postponement of the toxicities of WBRT. There have been recent attempts to predict patients who will have rapid DBF and require early WBRT [13, 28, 29] . A limitation of these prior models is that they do not predict the actual number of lesions at time of DBF.
There are several limitations to the current series. While the number of patients was large, the dataset was derived from several high volume academic centers in the United States and Canada. Given the retrospective nature of the dataset and the patient selection bias of North American academic centers, the results will need to be validated prospectively. Although the variables that were systematically collected by every institution were fairly comprehensive, systemic treatment details were not routinely collected by all institutions, and as such were not able to be reported in this study. Variation in the salvage philosophies at each of the centers may have influenced the decision to treat patients with salvage WBRT, as there were no standard guidelines across institutions regarding the use of SRS versus WBRT for salvage, with most institutions generally favoring salvage with SRS rather than WBRT when feasible. There were also no universal guidelines or protocol for MRI acquisition across institutions, in either the initial pre-treatment or follow-up setting. One implication of this is that similarly sized, small brain metastases may have potentially been identified and treated at different times across institutions, based upon differences in institutional MRI capabilities and frequency of follow-up imaging. 
